iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
IPO Year: 2016
Exchange: NASDAQ
Website: irhythmtech.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/2/2025 | $130.00 | Equal Weight → Overweight | Wells Fargo |
| 12/3/2024 | $86.00 | Equal Weight | Wells Fargo |
| 10/4/2024 | $78.00 | Neutral | Goldman |
| 6/20/2024 | $115.00 | Peer Perform → Outperform | Wolfe Research |
| 12/11/2023 | $110.00 | Neutral → Buy | Citigroup |
| 7/19/2023 | $130.00 | Outperform | Robert W. Baird |
| 2/7/2023 | $150.00 | Overweight | Wells Fargo |
| 11/7/2022 | Underperform → Peer Perform | Wolfe Research | |
| 6/9/2022 | $180.00 → $155.00 | Buy → Neutral | Citigroup |
| 4/6/2022 | $105.00 | Underperform | Wolfe Research |
SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) announced the results from two large-scale real-world studies presented at the American Diabetes Association's 85th Scientific Sessions (ADA 2025). The analyses reveal that cardiac arrhythmias are common and often occur early in people with type 2 diabetes (T2D)—especially those who also have chronic kidney disease (CKD). These findings suggest a critical opportunity to enhance early detection strategies in at-risk cardiometabolic populations. The studies examined longitudinal claims data from over 30 million U.S. adults, providing new insights into how arrhythmias—often asymptomatic—cluster around
SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. William Blair 45th Annual Growth Stock Conference on Wednesday, June 4, 2025, at 2:00 p.m. Central Time (12:00 p.m. Pacific Time)Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 2:40 p.m. Eastern Time (11:40 a.m. Pacific Time)Truist Securities MedTech Conference on Tuesday, June 17, 2025, at 1:40 p.m. Eastern Time (10:40 a.m. Pacific Time) Inter
iRhythm Zio® Long-Term Continuous Monitoring (LTCM) system — commercially introduced in Japan as the Zio® ECG Recording and Analysis System — brings AI-powered, continuous, uninterrupted ECG monitoring for up to 14 days to JapanLaunch is timely amid a growing demand for early, accurate detection of arrhythmias in Japan, the second largest ambulatory cardiac monitoring market in the world, where the prevalence is expected to rise alongside an aging population1-3 SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the commercial launch in Japan of its Zio® long-term continuous ECG monitoring (LTCM) system, commercially introduced in thi
SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $158.7 million, a 20.3% increase compared to first quarter 2024Gross margin of 68.8%, a 250-basis point increase compared to first quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $520.6 million as of March 31, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights Strong qu
SAN FRANCISCO, April 29, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced the company will be participating in the upcoming Bank of America Securities 2025 Health Care Conference. iRhythm's management is scheduled to present on Tuesday, May 13, 2025, 3:40 p.m. Pacific Time/6:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Events & Presentations" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading digit
Findings in a younger, commercially insured population build on Medicare-based CAMELOT results, expanding the generalizability of Zio LTCM's clinical impact across patient groups.Latest data showed Zio LTCM was associated with higher diagnostic yield and lower likelihood of repeat testing and cardiovascular events compared to all other LTCM products. SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) announced results from a large real-world retrospective analysis presented at the Heart Rhythm Society's annual meeting, HRS2025, held April 24–27 in San Diego, CA, The Assessment of Variation in AmbuLatory Cardiac MONitoring: Real-World Evidenc
SAN FRANCISCO, April 17, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 1, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading di
SAN FRANCISCO, April 16, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it has published its 2024 Corporate Sustainability Report, highlighting the company's efforts to build a sustainable and inclusive future. "iRhythm's core mission is to create a better world for patients by delivering better health and better insights through our trusted solutions and innovative technologies," said Sumi Shrishrimal, iRhythm's Chief Risk Officer and leader of Sustainability and Impact. "We accomplish this by being a responsible, ethical, and i
With three decades of spearheading advances in precision medicine and diagnostic technologies, King will accelerate the company's next phase of expansion. Turing Medical, a leader in precision brain mapping and targeting technologies, announced the appointment of Kevin King, former CEO of iRhythm Technologies, Affymetrix and Thomson Reuters Healthcare, as the company's new President and Chief Executive Officer (CEO). Turing Medical is developing advanced functional connectivity MRI processing techniques with the potential to generate highly detailed, personalized circuit maps that could help in the understanding and treatment of brain disorders. "Bringing Kevin King on as CEO marks a defi
SAN FRANCISCO, March 31, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced results from two large real-world retrospective analyses presented at the American College of Cardiology (ACC) 2025 Scientific Sessions in Chicago, IL. Drawing on data from more than 1.1 million patients who used iRhythm's Zio® long-term continuous monitoring (LTCM) ECG devices, these studies demonstrate that short-term (24–48-hour) monitoring, such as with Holter devices, fails to detect a significant proportion of actionable arrhythmias—even in patients reporting "daily symptoms"—and that Symptom–Rhythm Correlation (SRC) is notably low for most arrhythmias, underscoring that selecti
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4/A - iRhythm Technologies, Inc. (0001388658) (Issuer)